AGA2118 / Angitia Biopharma - LARVOL DELTA

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Angitia Incorporated Limited | Active, not recruiting ➔ Completed

Trial completion

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Angitia Incorporated Limited | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jun 2026 ➔ Sep 2026

Enrollment closed • Trial primary completion date

A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Angitia Incorporated Limited

New P1 trial

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) (clinicaltrials.gov) - P2 | N=379 | Active, not recruiting | Sponsor: Angitia Biopharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2027 ➔ Mar 2028 | Trial primary completion date: Aug 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Osteoporosis • Rheumatology

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women with Low Bone MasS (ARTEMIS) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Angitia Biopharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Osteoporosis • Rheumatology

ARTEMIS: A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: Angitia Incorporated Limited

New P2 trial • Osteoporosis • Rheumatology

AGA2118, a Bispecific Antibody Neutralizing Sclerostin and DKK1, Increased Bone Formation and Decreased Bone Resorption, Leading to a Rapid Increase in Bone Mass and Strength in an Ovariectomized Cynomolgus Monkey Model (ASBMR 2024) - No abstract available

Preclinical • Orthopedics • Osteoporosis • Rheumatology • DKK1

Long-Term Effects of AGA2118, a Bispecific Antibody that Neutralizes Both Sclerostin and DKK1, on Bone Formation and Bone Resorption Markers in Cynomolgus Monkeys (ASBMR 2024) - No abstract available

Orthopedics • Osteoporosis • Rheumatology • DKK1

AGA2118, a Bispecific Monoclonal Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and Led to Rapid BMD Gains in a First in Human, Single- and Multiple-Dose, Placebo-Controlled, Randomized Study (ASBMR 2024) - No abstract available

Clinical • P1 data • Osteoporosis • Rheumatology • DKK1

Preclinical and Clinical Pharmacokinetics of AGA2118, A Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 (DKK1), for the Treatment of Osteoporosis (ASBMR 2024) - No abstract available

PK/PD data • Preclinical • Osteoporosis • Rheumatology • DKK1

Long-Term Effects of AGA2118, a Bispecific Antibody that Neutralizes Both Sclerostin and DKK1, on Bone Formation and Bone Resorption Markers in Cynomolgus Monkeys (ASBMR 2024) - No abstract available

Orthopedics • Osteoporosis • Rheumatology • DKK1

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Angitia Biopharmaceuticals | Recruiting ➔ Completed

Trial completion • Osteoporosis • Rheumatology

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Angitia Biopharmaceuticals | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Osteoporosis • Rheumatology

A First-in-Human Study Evaluating AGA2118 in Postmenopausal Women (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Angitia Biopharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Osteoporosis • Rheumatology